SIBIA Neurosciences (SIBI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Larry Liebman who wrote (197)	7/20/1998 4:36:00 PM
From: scaram(o)uche	Read Replies (1) of 579

Larry: Either one of the ongoing trials might show tox that can't be managed effectively. You asked for a reason. You should also review all of the "risk factors" in the prospectus that was withdrawn (standard stuff). However, this is biotech's best leveraged business plan. You lose perhaps 50% on the downside, and you're filthy rich if everything works. 1508Y 1553A caspase-3 VGCC, migraine (pulled back in the last Lilly renewal) Bristol-Myers Squibb, Alzheimer's Novartis, epilepsy Novartis, stroke Lilly, VGCC stroke transcription- and fluorescence-based assays/patents Cognetix, Inc. equity In my opinion, the BMY program is sufficient, alone, to study SIBI at this price. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next